These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22865292)

  • 1. The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis.
    Voronov I; Ochotny N; Jaumouillé V; Owen C; Manolson MF; Aubin JE
    J Bone Miner Res; 2013 Jan; 28(1):108-18. PubMed ID: 22865292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy.
    Ochotny N; Voronov I; Owen C; Aubin JE; Manolson MF
    J Cell Biochem; 2013 Dec; 114(12):2823-33. PubMed ID: 23908015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice.
    Ochotny N; Flenniken AM; Owen C; Voronov I; Zirngibl RA; Osborne LR; Henderson JE; Adamson SL; Rossant J; Manolson MF; Aubin JE
    J Bone Miner Res; 2011 Jul; 26(7):1484-93. PubMed ID: 21305608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal pH Plays a Key Role in Regulation of mTOR Activity in Osteoclasts.
    Hu Y; Carraro-Lacroix LR; Wang A; Owen C; Bajenova E; Corey PN; Brumell JH; Voronov I
    J Cell Biochem; 2016 Feb; 117(2):413-25. PubMed ID: 26212375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
    Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
    Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity-independent targeting of mTOR to lysosomes in primary osteoclasts.
    Wang A; Carraro-Lacroix LR; Owen C; Gao B; Corey PN; Tyrrell P; Brumell JH; Voronov I
    Sci Rep; 2017 Jun; 7(1):3005. PubMed ID: 28592812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.
    Crasto GJ; Kartner N; Yao Y; Li K; Bullock L; Datti A; Manolson MF
    J Cell Biochem; 2013 Apr; 114(4):929-41. PubMed ID: 23129004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast-mediated bone resorption.
    Yang DQ; Feng S; Chen W; Zhao H; Paulson C; Li YP
    J Bone Miner Res; 2012 Aug; 27(8):1695-707. PubMed ID: 22467241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
    Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vacuolar-type H+-ATPase-mediated acidosis promotes in vitro osteoclastogenesis via modulation of cell migration.
    Kim JM; Min SK; Kim H; Kang HK; Jung SY; Lee SH; Choi Y; Roh S; Jeong D; Min BM
    Int J Mol Med; 2007 Mar; 19(3):393-400. PubMed ID: 17273786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).
    Kim K; Lee SH; Ha Kim J; Choi Y; Kim N
    Mol Endocrinol; 2008 Jan; 22(1):176-85. PubMed ID: 17885208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway.
    Yoon SH; Ryu Jy; Lee Y; Lee ZH; Kim HH
    J Bone Miner Res; 2011 Jun; 26(6):1217-29. PubMed ID: 21611964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
    Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
    Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
    Sahara T; Itoh K; Debari K; Sasaki T
    Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V-ATPase a3 isoform mutations identified in osteopetrosis patients abolish its expression and disrupt osteoclast function.
    Matsumoto N; Matsukawa R; Takahashi S; Kudo K; Sun-Wada GH; Wada Y; Nakanishi-Matsui M
    Exp Cell Res; 2020 Apr; 389(2):111901. PubMed ID: 32045577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.